Discovery of Highly Selective and Orally Active Lysophosphatidic Acid Receptor-1 Antagonists with Potent Activity on Human Lung Fibroblasts-Reference-Cited by-同舟云学术

Discovery of Highly Selective and Orally Active Lysophosphatidic Acid Receptor-1 Antagonists with Potent Activity on Human Lung Fibroblasts

Published:2012-08-29 Issue:17 Volume:55 Page:7920-7939
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Qian Yimin¹,Hamilton Matthew¹,Sidduri Achyutharao¹,Gabriel Stephen¹,Ren Yonglin¹,Peng Ruoqi¹,Kondru Rama¹,Narayanan Arjun¹,Truitt Terry¹,Hamid Rachid¹,Chen Yun¹,Zhang Lin¹,Fretland Adrian J.¹,Sanchez Ruben Alvarez¹,Chang Kung-Ching¹,Lucas Matthew¹,Schoenfeld Ryan C.¹,Laine Dramane¹,Fuentes Maria E.¹,Stevenson Christopher S.¹,Budd David C.¹

Affiliation:

1. Discovery Chemistry, ‡Discovery Inflammation and Respiratory Diseases, §Discovery Technology, ∥Pharmaceutical and Analytical Research, and ⊥Drug Metabolism and Pharmacokinetics, Small Molecule Research, Pharmaceutical Research and Early Drug Development, Hoffmann-La Roche, 340 Kingsland Street, Nutley, New Jersey 07110, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm301022v

Reference33 articles.

1. Novel therapeutic approaches for pulmonary fibrosis

2. Molecular Targets in Pulmonary Fibrosis

3. Autotaxin inhibitors: a perspective on initial medicinal chemistry efforts

4. Lysophosphatidic acid (LPA) receptors: Signaling properties and disease relevance

5. LPA Receptors: Subtypes and Biological Actions

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lysophosphatidic Acid Receptor 1 (LPA₁) Antagonists as Potential Migrastatics for Triple Negative Breast Cancer;ChemMedChem;2024-05-29

2. Design, synthesis and evaluation of new thiazolidin-4-ones as LPA ₁ receptor antagonists for breast cancer therapy;Future Medicinal Chemistry;2024-04-05

3. Discovery of the Novel, Orally Active, and Selective LPA1 Receptor Antagonist ACT-1016-0707 as a Preclinical Candidate for the Treatment of Fibrotic Diseases;Journal of Medicinal Chemistry;2024-02-13

4. Discovery of a Novel Orally Active, Selective LPA Receptor Type 1 Antagonist, 4-(4-(2-Isopropylphenyl)-4-((2-methoxy-4-methylphenyl)carbamoyl)piperidin-1-yl)-4-oxobutanoic Acid, with a Distinct Molecular Scaffold;Journal of Medicinal Chemistry;2024-02-13

5. In vitro pharmacological characterization of standard and new lysophosphatidic acid receptor antagonists using dynamic mass redistribution assay;Frontiers in Pharmacology;2023-11-14